Oral Answers to Questions

Debate between Robin Walker and Nick Smith

Thursday 3rd May 2018 Commons Chamber

[Nick Smith (Blaenau Gwent) (Lab)]

T2. The United Kingdom will have no role in approving new drugs through the European Medicines Agency during the transition period. Will the Minister confirm that that will have no impact on regulatory standards or patients’ access to vital medicines?

[The Parliamentary Under-Secretary of State for Exiting the European Union (Mr Robin Walker)]

I do not agree with the hon. Gentleman’s first statement. We have negotiated to ensure that we will be able to continue to work with agencies including the EMA during the implementation period. The EU has included specific language about being able to call on UK expertise, so we intend to continue co-ordination. As the Prime Minister has also set out, we are seeking, as part of our future partnership, a strong relationship with the EMA beyond our exit from the EU.